Strategic Advocates’s Veracyte VCYT Stock Holding History

Strategic Advocates’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2	Closed	-$85	–	597
2025 Q4	$85	Sell	2 -4	-67%	-$161	﹤0.01%	599
2025 Q3	$206	Buy	+6	New	+$172	﹤0.01%	564

Other funds holding VCYT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Strategic Advocates's VCYT Position: Q1 2026 in Review

Strategic Advocates sold out of Veracyte (VCYT) in Q1 2026, closing a stake of 2 shares — an estimated $85 sold.

Strategic Advocates first reported a position in VCYT in Q3 2025 and held it in 2 quarters. The position peaked at $206 in Q3 2025. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.

Strategic Advocates reported no remaining Veracyte position as of Q1 2026 after selling out during the quarter.
Strategic Advocates sold 2 Veracyte shares in Q1 2026, an estimated $85.
Strategic Advocates first reported a position in Veracyte in Q3 2025 and held it in 2 quarters.
Strategic Advocates's Veracyte position peaked at $206 in Q3 2025.
334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.